Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT05891795 Not yet recruiting - Acne Vulgaris Clinical Trials

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Mechanism-based acne treatment for transgender patients receiving testosterone currently does not exist and is an unmet medical need. This study explores clascoterone to treat testosterone induced acne. Many treatments we use to treat acne in females cannot be used in transgender males because they interfere with hormone therapy. Androgens have been associated with the development of acne vulgaris. Recently, a topical androgen receptor inhibitor cream (clascoterone) has been FDA-approved for the treatment of acne. However, clinical trials of clascoterone have excluded participants on exogenous hormones. Clascoterone has been hypothesized to be effective in the treatment of acne in transgender male participants on masculinizing hormone therapy, but it has never been studied or reported in the literature.

NCT ID: NCT05885217 Not yet recruiting - Acne Vulgaris Clinical Trials

Measurement of Serum microRNA in Acne Vulgaris Patient

Start date: August 2023
Phase:
Study type: Observational

The aim of the study is to: 1. Evaluation of serum microRNA in acne vulgaris and compare to control group 2. Evaluate correlation with acne vulgaris severity

NCT ID: NCT05869188 Not yet recruiting - Acne Vulgaris Clinical Trials

Effect of Systemic Isotretinoin on Serum Irisin Level in Acne Vulgaris Patients

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Acne vulgaris is a chronic inflammatory skin disease affecting the pilosebaceous unit. It is clinically characterized by comedones, papules, pustules, nodules, cysts and scarring on the face and trunk. The severity of the disease ranges from mild comedonal acne to severe nodulocystic acne which can be permanently disfiguring.In addition to the physical lesions, the disease can have a profound psychologic impact, contributing to low self-esteem, depression and anxiety.In addition to the physical lesions, the disease can have a profound psychologic impact, contributing to low self-esteem, depression and anxiety.

NCT ID: NCT05783778 Not yet recruiting - Acne Vulgaris Clinical Trials

Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Acne vulgaris is one if the most common chronic inflammatory skin disorders.Acne is characterized by forming of inflammatory and non inflammatory lesions mainly on the Face,neck,arms, upper trunk and back

NCT ID: NCT05737758 Not yet recruiting - Acne Clinical Trials

Investigating Clinical Trial Participation for Acne Patients

Start date: March 2024
Phase:
Study type: Observational

Participation in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This trial will scrutinize the experiences of patients diagnosed with acne as they take part in a separate medical intervention clinical trial. The focus will be on tracking the rates of completion and withdrawal among these individuals. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future acne patients.

NCT ID: NCT05666765 Not yet recruiting - Acne Vulgaris Clinical Trials

Comparison Between Isotretinoin, Silymarin and Both in the Treatment of Acne Vulgaris

Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

This study aims to compare the effects of isotretinoin and silymarin or both in treatment of acne and their effects on the level of IGF-1, SAA1 and malondialdehyde (MDA) in acne patients.

NCT ID: NCT05582434 Not yet recruiting - Acne Clinical Trials

Experience With Topical Acne Treatment

Start date: May 2024
Phase: Early Phase 1
Study type: Interventional

Acne is a chronic condition that typically requires the use of multiple medications.1 Medication adherence is especially challenging for patients with chronic diseases and often decreases over time, especially for those using topical medications.1 Nonadherence can result in multiple negative effects including treatment failure, increased healthcare costs, and decreased quality of life. Primary nonadherence refers to problems acquiring and starting treatment. Challenges to this form of nonadherence include a lack of knowledge, misunderstanding of usage, poor communication with provider, increased cost, and fear of side effects.2 Secondary nonadherence refers to when the patient does not use the medication as prescribed. Hurdles to secondary nonadherence include delayed results, increased complexity of treatment plan, adverse effects, busy lifestyle, and inconvenience.2

NCT ID: NCT05579171 Not yet recruiting - Acne Scars Clinical Trials

Lasers to Aid in Treatment of Acne Scars

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

To assess efficacy and safety of paired picosecond 755nm Alexandrite laser with focused lens array (PSAL; Picosure®, Cynosure, Westford, MA) and radiofrequency microneedling (RFM; Potenza™, Cynosure, Westford, MA) for treatment of facial, atrophic acne scars.

NCT ID: NCT05536193 Not yet recruiting - Acne Vulgaris Clinical Trials

Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris

Start date: September 10, 2022
Phase: Phase 4
Study type: Interventional

Acne Vulgaris (AV ) is a common skin disorder worldwide, affecting all ages and races, considered as a long term chronic inflammatory disease of the skin.It affects nearly 85% of adolescents and about 30% of adults which is known as post- adolescent acne that often occurs in individuals aged 25 years or older particularly women. Acne lesions, which may be papules, pustules, or nodules commonly affecting face, chest and back therefore acne patients may suffer from emotional distress due to its chronicity and potential outcomes which include physical scars and persistent hyperpigmentation. The pathophysiology of AV involves four factors: abnormal follicular keratinization, hyperseborrhea, Cutibacterium acnes proliferation in the pilosebaceous unit and inflammatory mediators released into the skin. Diet is considered to be one of the main factors influencing the induction and aggravation of acne, though this is still debatable. Previous researches have focused on glycemic load, and hyperinsulinemia which lead to an increase in the concentration of insulin-like growth factor (IGF-1), which has been reported to affect androgen metabolism and lipogenesis Additionally, IGF-1 has been shown to upregulate inflammatory cytokines. A correlation between the severity of acne and the level of serum IGF-1 has also been reported. Previous clinical studies showed that a low glycemic diet can decrease both the size of the sebaceous gland and the number of inflammatory lesions

NCT ID: NCT05471388 Not yet recruiting - Acne Vulgaris Clinical Trials

Assessment of Serum Asprosin Level in Male Patients With Acne Vulgaris

Start date: July 18, 2022
Phase: N/A
Study type: Interventional

Subject of interest is to evaluate serum level of asprosin in male patients with acne vulgaris, demonstrate the relation between acne vulgaris severity and level of asprosin in these patients & the relation between metabolic syndrome in acne vulgaris and level of asprosin.